These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

879 related items for PubMed ID: 26191276

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor α in high-grade serous ovarian carcinoma.
    Taube ET, Denkert C, Sehouli J, Unger U, Kunze CA, Budczies J, Dietel M, Braicu E, Darb-Esfahani S.
    Hum Pathol; 2017 Sep; 67():30-36. PubMed ID: 28414091
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-IIα, survivin, and E-cadherin.
    Raspollini MR, Luque RJ, Menendez CL, Bollito E, Brunelli M, Martignoni G, Montironi R, Cheng L, Blanca A, Baroni G, Minervini A, Lopez-Beltran A.
    Hum Pathol; 2016 Nov; 57():78-84. PubMed ID: 27473264
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Early stage epithelial ovarian cancers: a study of morphologic prognostic factors.
    Terzi A, Aktaş IY, Dolgun A, Ayhan A, Küçükali T, Usubütün A.
    Pathol Res Pract; 2013 Jun; 209(6):359-64. PubMed ID: 23643734
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Loss of ITM2A, a novel tumor suppressor of ovarian cancer through G2/M cell cycle arrest, is a poor prognostic factor of epithelial ovarian cancer.
    Nguyen TM, Shin IW, Lee TJ, Park J, Kim JH, Park MS, Lee EJ.
    Gynecol Oncol; 2016 Mar; 140(3):545-53. PubMed ID: 26691219
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. A novel nomogram based on LODDS to predict the prognosis of epithelial ovarian cancer.
    Xu XL, Cheng H, Tang MS, Zhang HL, Wu RY, Yu Y, Li X, Wang XM, Mai J, Yang CL, Jiao L, Li ZL, Zhong ZM, Deng R, Li JD, Zhu XF.
    Oncotarget; 2017 Jan 31; 8(5):8120-8130. PubMed ID: 28042955
    [Abstract] [Full Text] [Related]

  • 38. Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer.
    Miše BP, Telesmanić VD, Tomić S, Šundov D, Čapkun V, Vrdoljak E.
    Pathol Oncol Res; 2015 Apr 31; 21(2):347-56. PubMed ID: 25108408
    [Abstract] [Full Text] [Related]

  • 39. Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective.
    Elstrand MB, Sandstad B, Oksefjell H, Davidson B, Tropé CG.
    Acta Obstet Gynecol Scand; 2012 Mar 31; 91(3):308-17. PubMed ID: 22050605
    [Abstract] [Full Text] [Related]

  • 40. Expression and clinical significance of cortactin protein in ovarian neoplasms.
    Li A, Zhang L, Zhang X, Jin W, Ren Y.
    Clin Transl Oncol; 2016 Feb 31; 18(2):220-7. PubMed ID: 26243395
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 44.